IFNA1 and Hepatic fibrosis: Viral and host factors, such as HCV RNA titer, viral substitutions in HCV core or NS5A region, age, gender, liver fibrosis, and SNPs in IL-28B locus, are significantly associated with the effects of PEG-IFN and RBV combination therapy [7]–[15], but the precise molecular mechanisms remained unclear.